782 related articles for article (PubMed ID: 27716285)
41. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
[TBL] [Abstract][Full Text] [Related]
42. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
[TBL] [Abstract][Full Text] [Related]
43. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
44. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
[TBL] [Abstract][Full Text] [Related]
45. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.
Mross K; Frost A; Steinbild S; Hedbom S; Büchert M; Fasol U; Unger C; Krätzschmar J; Heinig R; Boix O; Christensen O
Clin Cancer Res; 2012 May; 18(9):2658-67. PubMed ID: 22421192
[TBL] [Abstract][Full Text] [Related]
46. [Long term follow-up results of anlotinib in the treatment of advanced renal cell carcinoma].
Song Y; Yihebali C; Yang L; Cui CX; Zhang W; Sun YK; Du CX; Zhou AP; Wang JW
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):765-770. PubMed ID: 32988160
[No Abstract] [Full Text] [Related]
47. Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.
Schöffski P; Jones SF; Dumez H; Infante JR; Van Mieghem E; Fowst C; Gerletti P; Xu H; Jakubczak JL; English PA; Pierce KJ; Burris HA
Eur J Cancer; 2011 Oct; 47(15):2256-64. PubMed ID: 21852114
[TBL] [Abstract][Full Text] [Related]
48. A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors.
Mross K; Richly H; Frost A; Scharr D; Nokay B; Graeser R; Lee C; Hilbert J; Goeldner RG; Fietz O; Scheulen ME
Cancer Chemother Pharmacol; 2016 Aug; 78(2):405-17. PubMed ID: 27349901
[TBL] [Abstract][Full Text] [Related]
49. First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors.
Koyama T; Shimizu T; Iwasa S; Fujiwara Y; Kondo S; Kitano S; Yonemori K; Shimomura A; Iizumi S; Sasaki T; Furuse J; Yamamoto N
Cancer Sci; 2020 Feb; 111(2):571-579. PubMed ID: 31797489
[TBL] [Abstract][Full Text] [Related]
50. Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
Weiss GJ; Hidalgo M; Borad MJ; Laheru D; Tibes R; Ramanathan RK; Blaydorn L; Jameson G; Jimeno A; Isaacs JD; Scaburri A; Pacciarini MA; Fiorentini F; Ciomei M; Von Hoff DD
Invest New Drugs; 2012 Dec; 30(6):2334-43. PubMed ID: 22160853
[TBL] [Abstract][Full Text] [Related]
51. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.
Rosen LS; Senzer N; Mekhail T; Ganapathi R; Chai F; Savage RE; Waghorne C; Abbadessa G; Schwartz B; Dreicer R
Clin Cancer Res; 2011 Dec; 17(24):7754-64. PubMed ID: 21976535
[TBL] [Abstract][Full Text] [Related]
52. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
Daud AI; Krishnamurthi SS; Saleh MN; Gitlitz BJ; Borad MJ; Gold PJ; Chiorean EG; Springett GM; Abbas R; Agarwal S; Bardy-Bouxin N; Hsyu PH; Leip E; Turnbull K; Zacharchuk C; Messersmith WA
Clin Cancer Res; 2012 Feb; 18(4):1092-100. PubMed ID: 22179664
[TBL] [Abstract][Full Text] [Related]
53. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
Britten CD; Kabbinavar F; Hecht JR; Bello CL; Li J; Baum C; Slamon D
Cancer Chemother Pharmacol; 2008 Mar; 61(3):515-24. PubMed ID: 17505827
[TBL] [Abstract][Full Text] [Related]
54. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study.
Cheng Y; Wang Q; Li K; Shi J; Liu Y; Wu L; Han B; Chen G; He J; Wang J; Lou D; Yu H; Wang S; Qin H; Li X
Br J Cancer; 2021 Aug; 125(3):366-371. PubMed ID: 34006926
[TBL] [Abstract][Full Text] [Related]
55. Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors.
Honda K; Yamamoto N; Nokihara H; Tamura Y; Asahina H; Yamada Y; Suzuki S; Yamazaki N; Ogita Y; Tamura T
Cancer Chemother Pharmacol; 2013 Sep; 72(3):577-84. PubMed ID: 23860959
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.
Liu Z; Gao S; Zhu L; Wang J; Zhang P; Li P; Zhang F; Yao W
Cancer Med; 2021 Nov; 10(21):7593-7600. PubMed ID: 34564939
[TBL] [Abstract][Full Text] [Related]
57. The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial.
Huang NS; Wei WJ; Xiang J; Chen JY; Guan Q; Lu ZW; Ma B; Sun GH; Wang YL; Ji QH; Wang Y
Thyroid; 2021 Dec; 31(12):1808-1813. PubMed ID: 34610756
[No Abstract] [Full Text] [Related]
58. Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors.
Mukohara T; Nagai S; Koshiji M; Yoshizawa K; Minami H
Cancer Sci; 2010 Oct; 101(10):2193-9. PubMed ID: 20707806
[TBL] [Abstract][Full Text] [Related]
59. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
[TBL] [Abstract][Full Text] [Related]
60. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
Drevs J; Siegert P; Medinger M; Mross K; Strecker R; Zirrgiebel U; Harder J; Blum H; Robertson J; Jürgensmeier JM; Puchalski TA; Young H; Saunders O; Unger C
J Clin Oncol; 2007 Jul; 25(21):3045-54. PubMed ID: 17634482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]